Abstract:
Objective: Four marketed oral anti-diabetic gliclazide tablets in Bangladesh have been
studied for their drug content, release profile and glucose lowering capacities. This sort of
study is a good indicator for in vivo evaluation of the quality of an oral anti-diabetic
preparation gliclazide.
Method: Marketed preparations of gliclazide from different manufacturers were randomly
chosen for this study. And the alloxan is used for the induction of diabetic in mice’s.
Glucometer in used to peak blood from tail vein of mice’s for measuring glucose level.
Result: The drug content was within the United State Pharmacopoeia (USP) specified limit
(73-87%) in all cases. The blood glucose levels were investigated after 7 days in alloxaninduced
diabetic (150mg/kg b.w) in mice’s (AIDMs); significant (P<0.05). After 14 days at
5hr of single dose (110 mg/kg body weight) treatment of the products; strongly significantly
(p<0.01) reduced blood glucose level 54.75%, 61.93%, 56.5% and 61%respectively; which
were consistent with anti-hyperglycemic effects of standard gliclazide (70%).
Conclusion: All the products were found to be qualified in very significantly lowering blood
glucose level. It may be inferred that of the gliclazide tablets of Bangladeshi manufacturers
complies with the standard specifications for drug contents, dissolution and antihyperglycemic
properties.
